Saturna Capital Corp Has $193,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Saturna Capital Corp grew its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 7.0% during the third quarter, Holdings Channel.com reports. The firm owned 20,553 shares of the biotechnology company’s stock after acquiring an additional 1,353 shares during the period. Saturna Capital Corp’s holdings in Iovance Biotherapeutics were worth $193,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of IOVA. Oppenheimer & Co. Inc. bought a new position in shares of Iovance Biotherapeutics in the first quarter valued at about $246,000. Sei Investments Co. grew its holdings in Iovance Biotherapeutics by 33.9% during the 1st quarter. Sei Investments Co. now owns 333,148 shares of the biotechnology company’s stock worth $4,937,000 after acquiring an additional 84,382 shares during the last quarter. US Bancorp DE increased its position in Iovance Biotherapeutics by 113.8% in the 1st quarter. US Bancorp DE now owns 31,557 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 16,800 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Iovance Biotherapeutics by 14.5% in the first quarter. ProShare Advisors LLC now owns 62,210 shares of the biotechnology company’s stock worth $922,000 after acquiring an additional 7,891 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Iovance Biotherapeutics by 9.2% during the first quarter. Vanguard Group Inc. now owns 24,915,300 shares of the biotechnology company’s stock worth $369,245,000 after purchasing an additional 2,102,480 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Down 7.1 %

NASDAQ:IOVA opened at $9.00 on Thursday. Iovance Biotherapeutics, Inc. has a 1-year low of $4.29 and a 1-year high of $18.33. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of -6.04 and a beta of 0.60. The business’s 50-day moving average price is $10.12 and its two-hundred day moving average price is $9.78.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The business had revenue of $58.56 million for the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. During the same period last year, the company posted ($0.46) EPS. Sell-side analysts predict that Iovance Biotherapeutics, Inc. will post -1.25 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. Piper Sandler downgraded Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $19.00 to $10.00 in a research report on Monday, July 29th. Finally, UBS Group assumed coverage on Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.33.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.